Publications by authors named "Natali Pflug"

Claim this Profile
C
Characteristics, patterns of care and outcomes of patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis.
Till Braun, Maren Keppel, Annika Dechow, Natali Pflug, Paul Liedgens

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
Annika Dechow, Sanna Timonen, Aleksandr Ianevski, Qu Jiang, Linus Wahnschaffe, Natali Pflug

Leukemia· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.
Till Braun, Michael Rade, Maximilian Merz, Hanna Klepzig, Florian Große, Natali Pflug

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.
Hanna Klepzig, Marco Herling, Natali Pflug, Till Braun

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Natali Pflug

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-LGLL: variety is the spice of this leukemia.
Natali Pflug

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations.
Natali Pflug, Annika Littauer, David Beverungen, Aleksandra Sretenovic, Linus Wahnschaffe

Front Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies.
Natali Pflug, Geothy Chakupurakal, Anna-Maria Fink, Sandra Robrecht, Marco Herling

Hemasphere· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Paula Cramer, Julia V Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Natali Pflug

Haematologica· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Natali Pflug, Paula Cramer, Sandra Robrecht, Jasmin Bahlo, Anne Westermann

Leuk Lymphoma· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, Carola Barth, Daniela Mauer, Natali Pflug

Hum Gene Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.
Othman Al-Sawaf, Paula Cramer, Valentin Goede, Michael Hallek, Natali Pflug

Ther Adv Hematol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.
Othman Al-Sawaf, Kirsten Fischer, Anja Engelke, Natali Pflug, Michael Hallek

Drug Des Devel Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
Udo Holtick, Marco Herling, Natali Pflug, Geothy Chakupurakal, Silke Leitzke

Ann Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Christian Maurer, Natali Pflug, Jasmin Bahlo, Sandra Kluth, Christina Rhein

Eur J Haematol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.
Natali Pflug, Sandra Kluth, Jörg J Vehreschild, Jasmin Bahlo, Daniela Tacke

Oncoimmunology· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Petra Langerbeins, Jasmin Bahlo, Christina Rhein, Paula Cramer, Natali Pflug

Future Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Paula Cramer, Susanne Isfort, Jasmin Bahlo, Stephan Stilgenbauer, Hartmut Döhner, Natali Pflug

Haematologica· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.
Natali Pflug, Jasmin Bahlo, Tait D Shanafelt, Barbara F Eichhorst, Manuela A Bergmann

Blood· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
Paula Cramer, Anna-Maria Fink, Raymonde Busch, Barbara Eichhorst, Clemens-Martin Wendtner, Natali Pflug

Leuk Lymphoma· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Georg Hopfinger, Raymonde Busch, Natali Pflug, Nicole Weit, Anne Westermann

Cancer· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the art treatment of chronic lymphocytic leukaemia.
Michael Hallek, Natali Pflug

Blood Rev· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lymphocytic leukemia.
Michael Hallek, Natali Pflug

Ann Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis